[go: up one dir, main page]

MX2022012033A - Agente terapeutico para infeccion por coronavirus. - Google Patents

Agente terapeutico para infeccion por coronavirus.

Info

Publication number
MX2022012033A
MX2022012033A MX2022012033A MX2022012033A MX2022012033A MX 2022012033 A MX2022012033 A MX 2022012033A MX 2022012033 A MX2022012033 A MX 2022012033A MX 2022012033 A MX2022012033 A MX 2022012033A MX 2022012033 A MX2022012033 A MX 2022012033A
Authority
MX
Mexico
Prior art keywords
coronavirus infection
treatment drug
infection treatment
coronavirus
pyrradine
Prior art date
Application number
MX2022012033A
Other languages
English (en)
Inventor
Tsutomu Sakurai
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MX2022012033A publication Critical patent/MX2022012033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La infección por coronavirus se puede tratar mediante la administración de una composición farmacéutica que comprende 6-fluoro-3-hidroxi-2-pirazincarboxamida o una sal de la misma como ingrediente activo a un paciente con infección por coronavirus con neumonía no grave.
MX2022012033A 2020-03-30 2021-03-26 Agente terapeutico para infeccion por coronavirus. MX2022012033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020061411 2020-03-30
JP2020156253 2020-09-17
PCT/JP2021/012858 WO2021200651A1 (ja) 2020-03-30 2021-03-26 コロナウイルス感染症治療剤

Publications (1)

Publication Number Publication Date
MX2022012033A true MX2022012033A (es) 2022-10-27

Family

ID=77927283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012033A MX2022012033A (es) 2020-03-30 2021-03-26 Agente terapeutico para infeccion por coronavirus.

Country Status (10)

Country Link
US (1) US20230127703A1 (es)
EP (1) EP4129291A4 (es)
JP (1) JPWO2021200651A1 (es)
CN (2) CN115884774A (es)
AU (1) AU2021245634A1 (es)
BR (1) BR112022019486A2 (es)
CA (1) CA3173148A1 (es)
MX (1) MX2022012033A (es)
TW (1) TW202203923A (es)
WO (1) WO2021200651A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022215616A1 (ja) * 2021-04-08 2022-10-13 富士フイルム富山化学株式会社 コロナウイルス感染症治療剤
EP4378462A4 (en) * 2021-07-30 2025-06-11 FUJIFILM Toyama Chemical Co., Ltd. THERAPEUTICAL FOR COVID-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112743B1 (en) 1998-08-20 2007-10-24 Toyama Chemical Co., Ltd. Nitrogenous heterocyclic carboxamide derivatives or salt thereof as antiviral agents
AU2010222029B2 (en) 2009-03-13 2014-03-27 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CN106749272B (zh) * 2012-03-13 2019-08-30 吉利德科学公司 用于抗病毒治疗的2’-取代的卡巴-核苷类似物
CN111265528A (zh) * 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
CN116589415A (zh) * 2020-02-01 2023-08-15 北京四环制药有限公司 一种法匹拉韦和/或其衍生物的精制方法

Also Published As

Publication number Publication date
TW202203923A (zh) 2022-02-01
AU2021245634A1 (en) 2022-10-20
EP4129291A1 (en) 2023-02-08
JPWO2021200651A1 (es) 2021-10-07
CN115884774A (zh) 2023-03-31
CN121360122A (zh) 2026-01-20
EP4129291A4 (en) 2024-04-10
CA3173148A1 (en) 2021-10-07
US20230127703A1 (en) 2023-04-27
WO2021200651A1 (ja) 2021-10-07
BR112022019486A2 (pt) 2022-11-16

Similar Documents

Publication Publication Date Title
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
ZA202406617B (en) Insulin containing pharmaceutical compositions
MX2012007410A (es) Compuestos antivirales novedosos.
FI3494972T3 (fi) Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
MX2022012033A (es) Agente terapeutico para infeccion por coronavirus.
MX2020005006A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
ZA202106768B (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2023012483A (es) Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.
MY170991A (en) Dosing regimens of celgosivir for the treatment of dengue
MX2023011297A (es) Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6).
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
EA202192483A1 (ru) Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства
RU2014141112A (ru) Метаболит илоперидона для применения при лечении психических расстройств
MX2008011321A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
EA201590350A1 (ru) Комбинации с пептидом с циклизованной основной цепью
MX2014015096A (es) Alimento para crustaceos.
RU2012114097A (ru) Терапевтический агент против хронической боли
ZA202102392B (en) Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy
MX2025010039A (es) Modulador dual de gen que codifica la enzima beta glucocerebrosidasa (gba1) y glucosilceramida sintasa (gcs)